Vaccine strategies for the treatment of lymphoma: preclinical progress and clinical trial update. Review uri icon

Overview

abstract

  • The clonal B-cell immunoglobulin idiotype found on the surface of lymphomas was the first targeted tumor-specific antigen, and combinations of idiotype with classical and novel adjuvants were shown to stimulate robust humoral and cellular responses, though clinical efficacy was more variable. Cellular and in situ vaccination to help target a wider array of tumor-specific antigens have also been able to stimulate tumor-specific cellular responses, though their clinical success has also been limited. Our growing understanding of the role of regulatory cells and the immunosuppressive tumor microenvironment, along with a wide variety of immunomodulatory agents developed as of late, offer promising adjuvants to potentiate the immune responses elicited by these vaccine protocols and to achieve durable remissions.

publication date

  • November 1, 2016

Research

keywords

  • Antigens, Neoplasm
  • B-Lymphocytes
  • Cancer Vaccines
  • Immunoglobulin Idiotypes
  • Lymphoma

Identity

Scopus Document Identifier

  • 85006989214

Digital Object Identifier (DOI)

  • 10.2217/imt-2016-0080

PubMed ID

  • 27993085

Additional Document Info

volume

  • 8

issue

  • 11